Even difficult-to-formulate active ingredients can be manufactured into core tablets: OSDrC technology and contract formulation development.
Introducing the nucleation of poorly formed cores! It is possible to encapsulate the inner drug in powder form within the outer layer.
The "OSDrC" technology allows for precise and flexible control of the inner core due to its variable double-structure pestle, enabling the production of higher quality core tablets than ever before, as well as facilitating the development of various new dosage forms. Since "OSDrC" does not require a supply process for the inner core, it can incorporate even difficult-to-form powders into the inner core. In other words, it is possible to encapsulate the inner drug in powder form with the outer layer, making it applicable to orally disintegrating tablets. Additionally, by placing pellets in the inner core, it is also possible to convert capsule formulations into tablet forms. Thus, it can significantly change the traditional formulation design process. 【Features】 ■ Does not require a supply process for the inner core ■ Can incorporate even difficult-to-form powders into the inner core ■ By placing pellets in the inner core, it is possible to convert capsule formulations into tablets ◎●◎ Sample Presentation ◎●◎ We will send tablet samples made using OSDrC technology to those who request them. Please indicate your request for a sample and the quantity in the inquiry form. *For more details about OSDrC technology, please refer to the OSDrC main brochure or feel free to contact us.
Inquire About This Product
basic information
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（2）
Download All Catalogs
Company information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.